Status:
COMPLETED
SOLIACS: Solian Solution in the Acute Setting
Lead Sponsor:
Sanofi
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
During this study the efficacy and safety profile will be evaluated of the use of amisulpride in the form of a solution in schizophrenic patients with an acute episode. The main purpose of the study ...
Eligibility Criteria
Inclusion
- schizophrenic in-patients with an acute episode
- aged between 18 and 65 years
- written informed consent
Exclusion
- pregnancy and breast-feeding
- breast cancer, prolactinoma, pheochromocytoma
- hypersensitivity to amisulpride or one of the other excipients
- contra-indications when using amisulpride as per the SmPC
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00245674
Start Date
June 1 2005
Last Update
April 10 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-aventis
Diegem, Belgium